Live webcast on Wednesday, August 28th at 3:40 PM ET
HOUSTON, Aug. 26,
2024 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting hard-to-treat tumors and viruses, today
announced that Walter Klemp,
Chairman and Chief Executive Officer of Moleculin will present at
LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
on Wednesday, August 28, 2024 at
3:40 PM ET.
Conference Details:
Conference: LIVE! with Webull Corporate Connect: Virtual
Biotech Investment Webinar
Date/Time: Wednesday, August
28, 2024 at 3:40 PM ET
Presenter: Walter
Klemp, Chairman and Chief Executive Officer
Registration Link: HERE
About Webull Financial
Webull Financial is a
leading online brokerage platform committed to empowering
self-directed investors with innovative tools and cutting-edge
technology. With low-cost trading on a wide range of assets,
advanced charting tools, and real-time market data, Webull is
revolutionizing the way individuals approach investing. The
user-centric approach and commitment to staying at the forefront of
industry trends underscore the mission to provide a seamless and
rewarding experience for traders of all levels. Through the Webull
Group, Webull Financial and its affiliates combine to serve tens of
millions of users from over 180 countries worldwide. Securities and
futures trading is offered to customers by Webull Financial LLC
("Webull Financial"), a broker-dealer registered with the
Securities and Exchange Commission (SEC) and a futures commission
merchant registered with the Commodity Futures Trading Commission
(CFTC). Webull Financial is a member of the Financial Industry
Authority (FINRA), the National Futures Association (NFA), and the
Securities Investor Protection Corporation (SIPC). All investing is
subject to risk, including the possible loss of principal. For more
information about Webull, visit www.webull.com.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
is a Phase 3 clinical stage pharmaceutical company advancing a
pipeline of therapeutic candidates addressing hard-to-treat tumors
and viruses. The Company's lead program, Annamycin, is a
next-generation anthracycline designed to avoid multidrug
resistance mechanisms and to eliminate the cardiotoxicity common
with currently prescribed anthracyclines. Annamycin is currently in
development for the treatment of relapsed or refractory acute
myeloid leukemia (AML) and soft tissue sarcoma (STS) lung
metastases.
The Company is initiating the MIRACLE (Moleculin
R/R AML AnnAraC Clinical Evaluation)
Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating
Annamycin in combination with cytarabine, together referred to as
AnnAraC, for the treatment of relapsed or refractory acute myeloid
leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the
Company believes it has substantially de-risked the development
pathway towards a potential approval for Annamycin for the
treatment of AML. This study is subject to appropriate future
filings with potential additional feedback from the FDA and their
foreign equivalents.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of viruses, as well as certain cancer
indications.
For more information about the Company, please visit
www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-live-with-webull-corporate-connect-healthcare-investment-webinar-302229774.html
SOURCE Moleculin Biotech, Inc.